Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix 1 GROWTH Key growth drivers grew +24% in Q4, representing 54% of IM sales Q4 sales1 Entresto sacubitri/valsartan Sales USD Million 949 Growth vs. PY USD Million Growth vs. PY CC 233 34% Cosentyx 1,243 134 13% (secukinumab) Kesimpta 147 (ofatumumab) 133 KISQALI 285 101 ribociclib zolgensma 342 88 458 Tafinlar. + Mekinist. 50 bal PROMACTA 518 47 (eltrombopag) ILARIS 284 44 (canakinumab) Xolair 373 38 Omalizumab ⒸJAKAVI 408 32 ruxolitinib Xiidra 134 26 MAYZENT. (siponimod) tablets 81 24 Key growth drivers 54% of IM sales, growing 24% in Q4 AimovigⓇ MayzentⓇ 54% PiqrayⓇ nm +24% vs. PY LutatheraⓇ 58% XiidraⓇ 36% 47% KymriahⓇ Kesimpta පු® 14% 38% IlarisⓇ 12% 29% 23% 15% Kisqali® ZolgensmaⓇ JakaviⓇ Tafinlar+MekinistⓇ PromactaⓇ 12% EntrestoⓇ 24% CosentyxⓇ Other² 46% Q4 2018 Q4 2019 Q4 2020 Q4 2021 nm not meaningful 1. Innovative Medicines division. 2. Includes Xolair®, Beovu®, Adakveo®, TabrectaⓇ, LuxturnaⓇ, Enerzair®, Atectura®, ScemblixⓇ and Leqvio®. Constant currencies (cc) is a non-IFRS measure; explanation of non- IFRS measures can be found on page 49 of Condensed Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 10 Investor Relations | Q4 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation